Heteroaryl and cycloalkyl sulfonamide hydroxamic acid inhibitors of matrix metalloproteinases.
Heteroaryl and cycloalkyl sulfonamide-hydroxamic acid MMP inhibitors were investigated. Of these, the pyridyl analogue 2 is the most potent and selective inhibitor of MMP-9 and MMP-13 in vitro.
Levin
J I
JI
Wyeth-Ayerst Research, Pearl River, NY 10965, USA. levinji@war.wyeth.com
Gu
Y
Y
Nelson
F C
FC
Zask
A
A
DiJoseph
J F
JF
Sharr
M A
MA
Sung
A
A
Jin
G
G
Cowling
R
R
Chanda
P
P
Cosmi
S
S
Hsiao
C L
CL
Edris
W
W
Wilhelm
J
J
Killar
L M
LM
Skotnicki
J S
JS
D000818:Animals; D020650:Combinatorial Chemistry Techniques; D006801:Humans; D006877:Hydroxamic Acids / Q000138:chemical synthesis / Q000737:chemistry / Q000494:pharmacology*; D020128:Inhibitory Concentration 50; D053509:Matrix Metalloproteinase 13; D061965:Matrix Metalloproteinase Inhibitors; D011480:Protease Inhibitors / Q000138:chemical synthesis* / Q000737:chemistry / Q000494:pharmacology; D013329:Structure-Activity Relationship; D013449:Sulfonamides / Q000138:chemical synthesis / Q000737:chemistry / Q000494:pharmacology; D062367:ortho-Aminobenzoates / Q000138:chemical synthesis / Q000737:chemistry / Q000494:pharmacology*
D006877:Hydroxamic Acids; D061965:Matrix Metalloproteinase Inhibitors; D011480:Protease Inhibitors; D013449:Sulfonamides; D062367:ortho-Aminobenzoates; C507079:MMP13 protein, human; D053509:Matrix Metalloproteinase 13